Provided by Tiger Trade Technology Pte. Ltd.

CLIMB BIO INC

14.95
-0.1000-0.66%
Post-market: 14.950.00000.00%16:15 EDT
Volume:1.49M
Turnover:22.05M
Market Cap:856.04M
PE:-17.91
High:15.07
Open:14.83
Low:14.16
Close:15.05
52wk High:18.33
52wk Low:1.54
Shares:57.26M
Float Shares:41.60M
Volume Ratio:0.63
T/O Rate:3.59%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.8347
EPS(LYR):-0.8974
ROE:-27.10%
ROA:-18.45%
PB:3.57
PE(LYR):-16.66

Loading ...

Chardan Initiates Climb Bio at Buy With $22 Price Target

MT Newswires Live
·
May 05

U.S. RESEARCH ROUNDUP-Applied Materials, Axsome Therapeutics, Onsemi

Reuters
·
May 05

Climb Bio Inc : Chardan Capital Markets Initiates Coverage With Buy Rating; Target Price $22

THOMSON REUTERS
·
May 05

Analysts Have Conflicting Sentiments on These Healthcare Companies: Climb Bio (CLYM), ICU Medical (ICUI) and Stryker (SYK)

TIPRANKS
·
May 04

Piper Sandler Remains a Buy on Climb Bio (CLYM)

TIPRANKS
·
May 04

BUZZ-U.S. STOCKS ON THE MOVE-Enterprise Products, Sherwin-Williams, Veradermics

Reuters
·
Apr 28

Climb Bio prices USD 110 million private placement at USD 9.5 per share

Reuters
·
Apr 28

Climb Bio Inc - Private Placement Expected to Close on or About April 29, 2026

THOMSON REUTERS
·
Apr 28

Press Release: Climb Bio, Inc. Announces $110.0 Million Private Placement

Dow Jones
·
Apr 28

Climb Bio announces annual shareholder meeting

Reuters
·
Apr 25

Analysts Offer Insights on Healthcare Companies: Passage Bio (PASG), Climb Bio (CLYM) and Zai Lab (ZLAB)

TIPRANKS
·
Apr 21

U.S. RESEARCH ROUNDUP-CNX Resources, P&G, Prologis

Reuters
·
Apr 21

Climb Bio Inc : Mizuho Initiates Coverage With Outperform Rating; Price Target $18

THOMSON REUTERS
·
Apr 15

Climb Bio announces annual shareholder meeting

Reuters
·
Apr 11

Climb Bio (CLYM) Gets a Buy from Piper Sandler

TIPRANKS
·
Apr 10

Climb Bio hosts R&D Spotlight webcast on budoprutug CD19 program opportunity

Reuters
·
Apr 08

Climb Bio Price Target Maintained With a $8.00/Share by BTIG

Dow Jones
·
Apr 08

Climb Bio says FDA grants Fast Track designation for budoprutug in pMN

Reuters
·
Apr 07

Climb Bio Announces FDA Fast Track Designation for Budoprutug for the Treatment of Primary Membranous Nephropathy

THOMSON REUTERS
·
Apr 07

Climb Bio Inc - to Share Initial Phase 2 Data in Second Half of 2026

THOMSON REUTERS
·
Apr 07